{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T21:02:56Z","timestamp":1785358976527,"version":"3.55.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ijgc.2026.104722","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T15:42:46Z","timestamp":1777131766000},"page":"104722","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Society of Gynecologic Oncology 2026: consolidating therapeutic shifts and opening new frontiers in gynecologic oncology"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2294-4013","authenticated-orcid":false,"given":"Ana Beatriz Tavares","family":"Filgueiras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela J\u00e9ssica","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9383-0227","authenticated-orcid":false,"given":"Pedro Ribeiro","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e9lica","family":"Nogueira-Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10496","key":"10.1016\/j.ijgc.2026.104722_bib1","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1016\/S0140-6736(25)01040-2","article-title":"Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial","volume":"405","author":"Olawaiye","year":"2025","journal-title":"Lancet"},{"issue":"10538","key":"10.1016\/j.ijgc.2026.104722_bib2","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(26)00462-9","article-title":"Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial","volume":"407","author":"Lorusso","year":"2026","journal-title":"Lancet"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2026.104722_bib3","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1200\/JCO.2025.43.16_suppl.5568","article-title":"Real-world analysis of folate receptor alpha (FR\u03b1; FOLR1) expression in pan-tumor samples from over 6000 patients in the US","volume":"43","author":"Krivak","year":"2025","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104722_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0001138","article-title":"HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients","volume":"2","author":"Tuefferd","year":"2007","journal-title":"PLoS One"},{"issue":"23","key":"10.1016\/j.ijgc.2026.104722_bib5","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.ijgc.2026.104722_bib6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104722_bib7","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104722_bib8","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S1470-2045(21)00342-9","article-title":"Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial","volume":"22","author":"Monk","year":"2021","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.ijgc.2026.104722_bib9","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1200\/JCO.21.00306","article-title":"Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed Stage III or IV ovarian cancer: placebo-controlled randomized Phase III trial (IMagyn050\/GOG 3015\/ENGOT-OV39)","volume":"39","author":"Moore","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104722_bib10","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.annonc.2025.05.009","article-title":"Dostarlimab and niraparib in primary advanced ovarian cancer","volume":"36","author":"Hardy-Bessard","year":"2025","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104722_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.101704","article-title":"Chemotherapy with or without pembrolizumab followed by maintenance with olaparib or placebo for first-line treatment of advanced BRCA non-mutated epithelial ovarian cancer: results from the randomized phase 3 ENGOT-OV43\/GOG-3036\/KEYLYNK-001 study","volume":"35","author":"Vergote","year":"2025","journal-title":"Int J Gynecol Cancer"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104722_bib12","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1136\/ijgc-2021-002933","volume":"31","author":"Monk","year":"2021","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104722_bib13","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.annonc.2025.11.020","article-title":"Durvalumab with carboplatin\/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer","volume":"37","author":"Harter","year":"2026","journal-title":"Ann Oncol"},{"issue":"36","key":"10.1016\/j.ijgc.2026.104722_bib14","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1200\/JCO.24.00668","article-title":"Atezolizumab combined with platinum and maintenance niraparib for recurrent ovarian cancer with a platinum-free interval >6 months: ENGOT-OV41\/GEICO 69-O\/ANITA phase III trial","volume":"42","author":"Gonz\u00e1lez-Mart\u00edn","year":"2024","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.ijgc.2026.104722_bib15","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1200\/JCO.23.00529","article-title":"Atezolizumab combined with bevacizumab and platinum-based therapy for platinum-sensitive ovarian cancer: placebo-controlled randomized Phase III ATALANTE\/ENGOT-ov29 trial","volume":"41","author":"Kurtz","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104722_bib16","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1200\/JCO-25-01210","article-title":"Atezolizumab with bevacizumab and nonplatinum chemotherapy for recurrent ovarian cancer: final results from the placebo-controlled AGO-OVAR 2.29\/ENGOT-ov34 phase III trial","volume":"44","author":"Harter","year":"2026","journal-title":"J Clin Oncol"},{"issue":"10538","key":"10.1016\/j.ijgc.2026.104722_bib17","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(26)00602-1","article-title":"Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65\/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study","volume":"407","author":"Colombo","year":"2026","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104722_bib18","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12935-021-02407-8","article-title":"Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier","volume":"22","author":"Vafaei","year":"2022","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.ijgc.2026.104722_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.103019","article-title":"Advances in treatment strategies for low-grade serous ovarian cancer","volume":"140","author":"Musacchio","year":"2025","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104722_bib20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.21037\/tcr-23-1161","article-title":"Current concept of low-grade serous ovarian carcinoma","volume":"13","author":"Nakayama","year":"2024","journal-title":"Transl Cancer Res"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104722_bib21","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2016.71.0632","article-title":"Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum","volume":"35","author":"Gershenson","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2026.104722_bib22","series-title":"Paper presented at: Proceedings of the Society of Gynecologic Oncology Annual Meeting on Women\u2019s Cancer; March 28-31, 2026","author":"Fader","year":"2026"},{"key":"10.1016\/j.ijgc.2026.104722_bib23","series-title":"Paper presented at: Proceedings of the Society of Gynecologic Oncology Annual Meeting on Women\u2019s Cancer; March 28-31, 2026","article-title":"Long-term efficacy and safety of avutometinib plus defactinib in patients with recurrent low-grade serous ovarian cancer: results from ENGOT-OV60\/GTG-UK\/GOG-3052 [abstract]","author":"Grisham","year":"2026"},{"issue":"23","key":"10.1016\/j.ijgc.2026.104722_bib24","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijgc.2026.104722_bib25","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.ygyno.2026.01.779","article-title":"Four-year survival outcomes with dostarlimab plus chemotherapy in dMMR\/MSI-H primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO\/GOG-3031\/RUBY trial","volume":"208","author":"Powell","year":"2026","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104722_bib26","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/ijgc-2021-002554","article-title":"Management of stage III and IVa uterine cancer","volume":"32","author":"Nero","year":"2022","journal-title":"Int J Gynecol Cancer"},{"issue":"20","key":"10.1016\/j.ijgc.2026.104722_bib27","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized Phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2026.104722_bib28","first-page":"TPS1107","article-title":"Trastuzumab pamirtecan (DB-1303\/BNT323), a novel HER2-targeting antibody-drug conjugate, in patients with HER2-expressing advanced solid tumors: phase 1\/2 study","volume":"41","author":"Xu","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2026.104722_bib29","series-title":"Presented at: Society of Gynecologic Oncology Annual Meeting on Women\u2019s Cancer","article-title":"Trastuzumab pamirtecan (DB-1303\/BNT323) in patients with previously treated HER2-expressing advanced\/metastatic endometrial cancer: first global clinical phase 2 data","author":"Xu","year":"2026"},{"key":"10.1016\/j.ijgc.2026.104722_bib30","unstructured":"Study of Trastuzumab Pamirtecan (DB-1303) in HER2-Expressing Recurrent Endometrial Cancer (Fern-EC-01\/ENGOT-EN25\/GOG-3105). NCT06340568. https:\/\/clinicaltrials.gov\/study\/NCT06340568. Accessed date: April 13 2026"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104722_bib31","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1001\/jamaoncol.2024.3660","article-title":"Frequency of ERBB2-low expression in endometrial cancer","volume":"10","author":"Krakstad","year":"2024","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104722_bib32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2009.09.025","article-title":"Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study","volume":"116","author":"Fleming","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.104722_bib33","series-title":"Paper presented at: Society of Gynecologic Oncology Annual Meeting on Women\u2019s Cancer","article-title":"DESTINY-Endometrial01: a phase III study of trastuzumab deruxtecan in combination with rilvegostomig or pembrolizumab versus standard of care in patients with HER2-positive advanced or recurrent endometrial cancer","author":"Makker","year":"2026"},{"key":"10.1016\/j.ijgc.2026.104722_bib34","series-title":"Paper presented at: Society of Gynecologic Oncology Annual Meeting on Women\u2019s Cancer","article-title":"DESTINY-Endometrial02 (DE-02; GOG-3122\/ENGOT-en30): A phase III study of trastuzumab deruxtecan versus standard of care in patients with HER2-positive high-risk endometrial cancer","author":"Westin","year":"2026"},{"key":"10.1016\/j.ijgc.2026.104722_bib35","series-title":"Paper presented at: Society of Gynecologic Oncology Annual Meeting on Women\u2019s Cancer","article-title":"Sacituzumab tirumotecan (Sac-TMT) plus pembrolizumab in participants with recurrent or metastatic cervical cancer: results from the phase II 2870-002\/SKB264-II-06 study","author":"Wu","year":"2026"},{"issue":"suppl 1","key":"10.1016\/j.ijgc.2026.104722_bib36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/ijgo.13870","article-title":"Obesity and gynecological cancers: a toxic relationship","volume":"155","author":"Wichmann","year":"2021","journal-title":"Int J Gynecol Obstet"},{"issue":"10333","key":"10.1016\/j.ijgc.2026.104722_bib37","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0140-6736(22)00323-3","article-title":"Endometrial cancer","volume":"399","author":"Crosbie","year":"2022","journal-title":"Lancet."},{"key":"10.1016\/j.ijgc.2026.104722_bib38","series-title":"Paper presented at: Society of Gynecologic Oncology Annual Meeting on Women\u2019s Cancer","article-title":"Glucagon-like peptide-1 receptor agonists are associated with a reduced cumulative incidence of obesity-associated cancers in obese non-diabetic women","author":"Hsu","year":"2026"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104722_bib39","first-page":"64","article-title":"Weight management and physical activity throughout the cancer care continuum","volume":"68","author":"Demark-Wahnefried","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104722_bib40","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.ijgc.2026.104722_bib41","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40364-025-00765-3","article-title":"Glucagon-like peptide 1 receptor agonists and cancer risk: advancing precision medicine through mechanistic understanding and clinical evidence","volume":"13","author":"Lin","year":"2025","journal-title":"Biomark Res"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26002537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26002537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T20:22:52Z","timestamp":1785356572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26002537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1048891X26002537"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104722","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Society of Gynecologic Oncology 2026: consolidating therapeutic shifts and opening new frontiers in gynecologic oncology","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104722","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104722"}}